Author:
Kreua-ongarjnukool Narumol,Soomherun Nopparuj,Thumsing Niyomthai Saowapa,Chumnanvej Sorayouth
Abstract
Drug delivery systems using aliphatic polyester nanoparticles are usually prepared via an emulsion process. These nanoparticles can control drug release and improve pharmacokinetics. Aliphatic polyesters are linear polymers containing ester linkages, showing sensitivity to hydrolytic degradation. The byproducts then promote autocatalytic degradation. These byproducts could enter the Krebs cycle and be eliminated from the body, resulting in the high biocompatibility of these nanoparticles. The properties of these polyesters are linked to the drug release rate due to biodegradation, i.e., polymer crystallinity, glass transition temperature, polymer hydrophobicity, and molecular weight (MW), all of which relatively influence hydrolysis. Mathematical equations have been used to study the factors and mechanisms that affect drug dissolution compared to experimental release data. The equations used as models for predicting the kinetics of drug release include the zero-order, first-order, Higuchi, Hixson-Crowell, and Korsmeyer-Peppas equations. Aliphatic polyester-based controlled drug delivery has surrounded much of the current activity in the estimation parameters of nanoparticles and stimulated additional research. Polymeric nanoparticles have potential in a wide range of applications, such as in biotechnology, vaccine systems, and the pharmaceutical industry. The main goal of this chapter is to discuss aliphatic polyester nanoparticles as drug carrier systems.
Reference59 articles.
1. Chumnanvej S, Sarnvivad P. Retrospective 5-year clinical outcome of interdisciplinary treatment for ruptured cerebral arteriovenous malformation: The lesson learned. Archives of Medicine. 2015;7(44):1-7
2. Alahamd Y, Swehli H, Rahhal A, Sardar S, Elhassan M, Alsamel A, et al. Calcium channel blockers. In: Ambrosi P, Ahmad R, Abdullahi A, Agrawal A, editors. New Insight into Cerebrovascular Diseases—An Updated Comprehensive Review. London: IntechOpen; 2020. pp. 216-233
3. Kasuya H. Development of nicardipine prolonged-release implants after clipping for preventing cerebral vasospasm: From laboratory to clinical trial. Acta Neurochirurgica Supplement. 2013;115:41-44
4. Barth M, Pena P, Seiz M, Thomé C, Muench E, Weidauer S, et al. Feasibility of intraventricular nicardipine prolonged release implants in patients following aneurysmal subarachnoid haemorrhage. British Journal of Neurosurgery. 2011;25(6):677-683
5. Thomé C, Seiz M, Schubert GA, Barth M, Vajkoczy P, Kasuya H, et al. Nicardipine pellets for the prevention of cerebral vasospasm. Acta Neurochirurgica Supplement. 2011;110(Pt 2):209-211
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A review on Advancements in Nanoparticles Based Pulmonary Drug Delivery;International Journal of Newgen Research in Pharmacy & Healthcare;2024-06-30